Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYLANID vs PARSABIV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.
Calcium-sensing receptor (Ca SR) agonist; increases the sensitivity of the Ca SR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.
Heart failure,Atrial fibrillation,Atrial flutter
Secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis
0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.
Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.
Terminal half-life 33–36 hours (anuric patients up to 110 hours); requires dose adjustment in renal impairment.
Terminal elimination half-life of 3-5 days, supporting once-weekly subcutaneous dosing.
Hepatic metabolism via hydrolysis and conjugation; not significantly metabolized by CYP enzymes.
Primarily metabolized via amide hydrolysis and oxidation, with involvement of CYP3A4, CYP2D6, and CYP1A2 as minor pathways.
Renal (≈70% as unchanged drug), biliary/fecal (≈30%)
Renal: negligible (<2% unchanged); fecal: primary route via biliary elimination of intact drug and metabolites; not dialyzable.
25–30% bound to albumin.
Approximately 90-95% bound to albumin.
7.5–10 L/kg; wide distribution indicating extensive tissue binding.
Approximately 0.29-0.46 L/kg, indicating distribution limited to extracellular fluid.
Oral: 70–85% (variable, dependent on gastrointestinal absorption).
Subcutaneous: approximately 50% (range 40-60%).
GFR <30 m L/min: reduce dose by 50% and extend dosing interval to every 12-24 hours. GFR 30-50 m L/min: consider 25% dose reduction. Monitor digoxin levels.
Contraindicated in patients with estimated glomerular filtration rate (e GFR) less than 15 m L/min/1.73 m². No dose adjustment required for e GFR ≥ 15 m L/min/1.73 m².
Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use with caution, reduce dose by 50% and monitor levels. Not recommended in severe hepatic impairment.
No specific guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C) due to lack of data.
Loading dose: 10-15 mcg/kg IV over 5 minutes. Maintenance: 5-10 mcg/kg orally every 8-12 hours. Maximum daily dose: 250 mcg in children <2 years, 500 mcg in older children.
Safety and efficacy not established in pediatric patients; no approved dosing recommendations.
Initiate with 50% of usual adult dose due to reduced renal function and increased sensitivity. Maximum loading dose: 0.2 mg IV. Maintenance: 0.1 mg every 12 hours. Monitor electrolytes and ECG.
No specific dose adjustments recommended; clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed.
None.
None.
Risk of digitalis toxicity; monitor renal function and electrolytes; caution in hypokalemia, hypomagnesemia, and hypercalcemia.
Hypocalcemia,Seizures potentially due to severe hypocalcemia,QT interval prolongation,Gastrointestinal bleeding,Adynamic bone disease
Ventricular fibrillation,Hypersensitivity to cardiac glycosides,Digitalis toxicity
Hypocalcemia
Avoid high-potassium foods (bananas, oranges, spinach) unless directed; hypokalemia increases toxicity. Take with food to reduce GI upset. Do not take with high-fiber meals as may reduce absorption.
No specific food interactions. However, patients should adhere to a renal diet as prescribed, which may include restrictions on phosphorus and calcium intake. Avoid calcium-containing supplements or binders without medical advice due to risk of hypercalcemia.
Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Second and third trimesters: Maternal toxicity (arrhythmias, electrolyte disturbances) may cause fetal hypoxia or growth restriction. Avoid toxicity. Category C.
In animal reproduction studies, intravenous etelcalcetide administered to pregnant rats during organogenesis at doses 2.5 times the maximum recommended human dose (MRHD) based on AUC caused increased incidences of fetal skeletal variations and reduced fetal body weight. In rabbits, no adverse fetal effects were observed at doses up to 0.7 times the MRHD. No adequate and well-controlled studies in pregnant women exist. In the first trimester, exposure poses unknown but potential teratogenic risk. During the second and third trimesters, the drug may cause fetal hypocalcemia due to PTH suppression. Use only if potential benefit justifies potential risk.
Acylanid is excreted into breast milk in low amounts (M/P ratio not established; estimated <1% of maternal dose). No adverse effects reported in nursing infants. Use with caution, monitor infant for bradycardia or arrhythmias.
No data on etelcalcetide presence in human milk, effects on breastfed infants, or milk production. Animal studies show etelcalcetide is present in rat milk. M/P ratio unknown. Because of the potential for serious adverse reactions including hypocalcemia in nursing infants, advise patients not to breastfeed during treatment and for two weeks after the last dose.
Increased volume of distribution and renal clearance in pregnancy may reduce serum levels; monitor drug levels and adjust dose to maintain therapeutic range (0.5-2 ng/m L). Start at lower doses if hypokalemia or preeclampsia present.
No specific dosage adjustments are recommended for pregnancy due to lack of pharmacokinetic data in pregnant women. However, because of the potential for hypocalcemia, more frequent monitoring of serum calcium is advised, and dose adjustments may be needed to maintain calcium levels within target range. The effect of pregnancy on etelcalcetide pharmacokinetics is unknown.
Acylanid (lanatoside C) is a digitalis glycoside with rapid onset (IV 10-30 min) and moderate duration; use in atrial fibrillation with rapid ventricular response, especially in acute settings. Monitor renal function due to renal elimination; toxicity risk increases with hypokalemia, hypomagnesemia, hypercalcemia. Adjust dose in renal impairment (Cr Cl <50 m L/min). Therapeutic drug monitoring: target serum level 0.5-2 ng/m L (drawn >6-8 hours post-dose).
Monitor serum calcium closely; PARSABIV (etelcalcetide) is a calcimimetic that lowers PTH and serum calcium. Initiate only if corrected serum calcium is above the lower limit of normal. Administer intravenously three times per week during hemodialysis. Dose adjustments needed based on serum calcium and PTH levels. Avoid use with other calcimimetics. May cause significant hypocalcemia, especially in patients with adynamic bone disease.
Take exactly as prescribed; do not skip doses or double up. Missed dose: take if within 12 hours, otherwise skip.,Monitor for signs of toxicity: nausea, vomiting, diarrhea, visual disturbances (yellow-green halos, blurred vision), confusion, irregular heartbeat.,Avoid OTC medications without consulting prescriber, especially antacids, laxatives, and antiarrhythmics.,Keep regular appointments for blood tests (digoxin level, kidney function, electrolytes).,Report weight gain >2 lbs/day, swelling, shortness of breath, or palpitations.
This medication is given intravenously during your dialysis sessions three times a week.,It works by lowering parathyroid hormone (PTH) levels to help manage secondary hyperparathyroidism.,You will need regular blood tests to monitor your calcium and PTH levels.,Report symptoms of low calcium such as muscle cramps, numbness, tingling around the mouth, or seizures.,Do not take any other medications for secondary hyperparathyroidism unless prescribed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYLANID vs PARSABIV, answered by our medical review team.
ACYLANID is a Cardiac Glycoside that works by Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.. PARSABIV is a Calcimimetic that works by Calcium-sensing receptor (Ca SR) agonist; increases the sensitivity of the Ca SR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYLANID and PARSABIV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYLANID is: 0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.. The standard adult dose of PARSABIV is: Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYLANID and PARSABIV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYLANID is classified as Category C. Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Secon. PARSABIV is classified as Category C. In animal reproduction studies, intravenous etelcalcetide administered to pregnant rats during organogenesis at doses 2.5 times the maximum recommended human dose (MRHD) based on A. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.